Baidu
map

医疗大数据大热,Flatiron Health 获 1.3 亿美元融资

2015-01-18 崔绮雯 ifanr

Google Venture 自从 2009 年成立以来,已经投资了互联网、软件、生物技术、医疗等各个领域大小 230 家公司,但是像今天这样“大手笔”还是少数——基于癌症大数据分析的医疗初创公司 Flatiron Health 今天获得了 1.3 亿美元的 B 轮融资,领头机构是 Google Venture。 这是 Google Venture 成立 5 年来第四大金额的投资,也是

your-news-story-here-604

Google Venture 自从 2009 年成立以来,已经投资了互联网、软件、生物技术、医疗等各个领域大小 230 家公司,但是像今天这样“大手笔”还是少数——基于癌症大数据分析的医疗初创公司 Flatiron Health 今天获得了 1.3 亿美元的 B 轮融资,领头机构是 Google Venture。

这是 Google Venture 成立 5 年来第四大金额的投资,也是 Google Venture 在医疗软件领域的最大投资。而在此次投资之后,Google X 的总监 Andrew Conrad 也成为 Flatiron Health 的董事会成员。

而这次投资,也代表着 Google Venture 对医疗数据分析领域的前景看好,其负责人 Bill Maris 称,他们也是对 Flatiron Health 团队的产品信心满满。

Flatiron Health 这个成立于 2012 年的初创公司,瞄准的是一个少人踏足的数据分析领域——目前,仅有 4% 的癌症病人会参与临床试验,这也就意味着,有 96% 癌症病患的治疗信息是无法轻易获取。而 Flatiron Health 正在做的,就是收集临床以及基因数据、患者的治疗结果、医生的治疗手记以及费用等等,然后将这些信息呈献给肿瘤学家,分析过往治疗的效果以及研究新的治疗 手段。

全美现在有约 1000 名肿瘤学家正在使用 Flatiron Health 的数据。而该公司的创始人 Nathaniel Turner 表示,他们会利用这笔 1.3 亿美元收购肿瘤医疗记录的云端服务 Alto Solutions。经过收购和整合,让医生能够随时随地的调用 Flatiron 的数据库进行分析,并且完善病患的电子医疗记录,丰富数据库。

医疗是一个变革相对较慢的行业,专业医生的培养需要较长的周期以及较高的门槛,医生的数量已经不足以应付海量的病患的需求。应运而生的医疗大数据分析,正走在风口浪尖上。

题图来自:diginomica.com

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-02-16 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-01-20 zhao4618
  4. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-01-20 july_979
  5. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1860988, encodeId=b8c61860988c2, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Feb 16 18:20:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735938, encodeId=cbab1e35938a1, content=<a href='/topic/show?id=21be3492589' target=_blank style='color:#2F92EE;'>#医疗大数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34925, encryptionId=21be3492589, topicName=医疗大数据)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0ea34047589, createdName=aids224, createdTime=Thu Oct 29 00:20:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459017, encodeId=ed65145901ea7, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524186, encodeId=ba551524186c8, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621515, encodeId=9b6e1621515d7, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Tue Jan 20 11:20:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14513, encodeId=5e5a1451334, content=接地气, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lifefamily, createdTime=Sun Jan 18 22:56:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-01-18 lifefamily

    接地气

    0

相关资讯

PCORnet:美国大数据让临床研究从梦想走进现实

过去5年,仅心血管领域,便有2700份临床指南或共识,然而仅314项(11%)是基于A级证据,即多中心随机对照研究的结果。近半数指南共识仅仅基于专家观点。因此,迫切需要提供更强有力的临床医学证据 以患者为中心的结局研究机构(Patient-Centered Outcomes Research Institute ,PCORI)发布了这个数据库PCORnet, 它主要用于比较临床研究。在20

大数据可以让“外滩踩踏事故”悲剧不再重现?

文/李俊慧 逝者应安息,生者当反思。 如果知道是这样的结果,相信很多人都会避而远之,而不是趋之若鹜。 2015年第一天,上海传来噩耗:2014年12月31日晚23时35分许,上海外滩陈毅广场发生群众拥挤踩踏事故,致35人死亡,43人受伤。 事故原因已开始调查,随着时间的变化,有关数字可能还会变化,与其抱怨、质疑是否存在瞒报,或许反思已有的技术或应用能否发挥“能量”,防范此类悲剧的不

在大数据中找到新机遇的巢式病例-对照研究

一、巢式病例-对照研究 病例对照研究是临床研究中较为常用的设计方案。如果将临床研究划分为“探索、培育、验证”3个阶段的话,病例对照研究是探索阶段的重要工具,通过病例对照研究,人们能够基于现成的资料,迅速的发现有价值的科学规律,进而开展进一步研究。但是正所谓鱼和熊掌不可兼得,病例对照研究通常从病例开始,再根据病例去寻找合理、可用的对照,并回顾性的收集数据;这一做法虽然效率高,但是往往会收到

生物领域的大数据有多值钱?

36氪曾多次报道过这家基因技术公司,好吧,我们这么关心这家公司的原因也许是因为它的联合创始人之一Anne Wojcicki正是谷歌联合创始人Sergey Brin的妻子(分居了?)。目测我身边不少生科妹子(以及女性老师)都很羡慕她有一位有钱的丈夫可以为自己做实验买单。 言归正传,23andMe是一家好公司,Anne Wojcicki也被认为是一位好科学家。但基因技术涉及人类隐私以及令很多科研

J Am Med Inform Assoc:美国将采用3千万患者大数据研究阿司匹林疗效

        一项大数据研究将搞清不同剂量的阿司匹林对于心脏病有何种疗效。         图片来源:Richard Levine/Alamy 医疗卫生领域迄今最大的一项大数据试验终于设定了第一个研究目

节约医生的诊疗时间:Lumiata用大数据建医疗图谱,提高诊疗的精准性

医疗软件公司Lumiata 获得 600 万美元 A 轮融资 ,至今它已获得总计 1 千万美元的投资。Lumiata 是首家提出“医疗图谱(medical graph)”的公司,他们把电子病历和病理生理学等数据整合起来,并通过图谱分析的方式去模拟人类的多维推理过程,进而预测出病人会需要什么、以及何时需要。利用这些数据,Lumiata 还可以去分析和预测一个人群整体的健康状态。通过把数据转

Baidu
map
Baidu
map
Baidu
map